Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The 20 Most sultry Style of the Time - 2Check out the exclusive pitch deck Valerie Health used to raise $30 million from Redpoint Ventures to automate healthcare faxes
- 3Extraordinary Snowboarding Objections All over the Planet
- 4Whale stranded off Germany for days free again
- 5Mars spacecraft images pinpoint comet 3I/ATLAS's path with 10x higher accuracy. This could help us protect Earth someday
- Turning to turkey’s tryptophan to boost mood? Not so fast
- The Force of Care: Living with Goal
- Green Inflections: A Manual for Inside Plants
- Signature Scents: A Manual for Outstanding Fragrances
- Ancient meditation practices find new life in modern religious communities across America
- The 15 Most Compelling Books in History
- Al-Sharaa denies he called for 80% of Syrians to return from Germany
- When Would it be a good idea for you to Look for Help from a Criminal Legal counselor?
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
